Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Garnero

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Clinical Endocrinology|April 28, 2011
Osteocalcin-insulin relationship in obese children: a role for the skeleton in energy metabolismGaël Y Rochefort, Emilie Rocher, Priscilla C Aveline, et al.
Modern Rheumatology|June 25, 2010
Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI studyJun Hashimoto, Patrick Garnero, Désirée van der Heijde, et al.
Modern Rheumatology|May 20, 2009
A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugsJun Hashimoto, Patrick Garnero, Désirée van der Heijde, et al.
The Journal of Rheumatology|April 1, 2005
Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohortPatrick Garnero, Bernard Mazières, Alice Guéguen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 18, 2011
Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnoverBasem M Abdallah, Anne-Christine Bay-Jensen, Bhuma Srinivasan, et al.
Arthritis and Rheumatism|May 18, 2004
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritisRobert Landewé, Piet Geusens, Maarten Boers, et al.
Inflammatory Bowel Diseases|January 28, 2015
Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's diseaseGilles Boschetti, Patrick Garnero, Driffa Moussata, et al.
Bone|August 15, 2009
Rapid and robust response of biochemical markers of bone formation to teriparatide therapySarah J Glover, Richard Eastell, Eugene V McCloskey, et al.
Annals of the Rheumatic Diseases|October 29, 2010
Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritisPascal Richette, Christine Poitou, Patrick Garnero, et al.
Arthritis and Rheumatism|November 13, 2002
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA studyPatrick Garnero, Robert Landewé, Maarten Boers, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Clinical Endocrinology|April 28, 2011
Osteocalcin-insulin relationship in obese children: a role for the skeleton in energy metabolismGaël Y Rochefort, Emilie Rocher, Priscilla C Aveline, et al.
Modern Rheumatology|June 25, 2010
Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI studyJun Hashimoto, Patrick Garnero, Désirée van der Heijde, et al.
Modern Rheumatology|May 20, 2009
A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugsJun Hashimoto, Patrick Garnero, Désirée van der Heijde, et al.
The Journal of Rheumatology|April 1, 2005
Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohortPatrick Garnero, Bernard Mazières, Alice Guéguen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 18, 2011
Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnoverBasem M Abdallah, Anne-Christine Bay-Jensen, Bhuma Srinivasan, et al.
Arthritis and Rheumatism|May 18, 2004
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritisRobert Landewé, Piet Geusens, Maarten Boers, et al.
Inflammatory Bowel Diseases|January 28, 2015
Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's diseaseGilles Boschetti, Patrick Garnero, Driffa Moussata, et al.
Bone|August 15, 2009
Rapid and robust response of biochemical markers of bone formation to teriparatide therapySarah J Glover, Richard Eastell, Eugene V McCloskey, et al.
Annals of the Rheumatic Diseases|October 29, 2010
Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritisPascal Richette, Christine Poitou, Patrick Garnero, et al.
Arthritis and Rheumatism|November 13, 2002
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA studyPatrick Garnero, Robert Landewé, Maarten Boers, et al.
Pageof 12